SAREPTA THERAPEUTICS, INC. Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments
SAREPTA THERAPEUTICS, INC. (SRPT) reported Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Income Statement › Other Income
us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1 · last filed 2026-03-02
- SAREPTA THERAPEUTICS, INC. change in unrealized gain (loss) on fair value hedging instruments for the quarter ending 2025-12-31 was $11.10M.
- SAREPTA THERAPEUTICS, INC. change in unrealized gain (loss) on fair value hedging instruments for the quarter ending 2025-09-30 was -$11.10M.
- SAREPTA THERAPEUTICS, INC. change in unrealized gain (loss) on fair value hedging instruments for the quarter ending 2025-06-30 was $0.00.
- SAREPTA THERAPEUTICS, INC. change in unrealized gain (loss) on fair value hedging instruments for the quarter ending 2025-03-31 was $0.00.
- SAREPTA THERAPEUTICS, INC. change in unrealized gain (loss) on fair value hedging instruments for fiscal 2025 was $0.00.
- SAREPTA THERAPEUTICS, INC. change in unrealized gain (loss) on fair value hedging instruments for fiscal 2024 was -$7.84M.
- SAREPTA THERAPEUTICS, INC. change in unrealized gain (loss) on fair value hedging instruments for fiscal 2023 was -$1.20M, a 117.91% decline from fiscal 2022.
- SAREPTA THERAPEUTICS, INC. change in unrealized gain (loss) on fair value hedging instruments for fiscal 2022 was $6.70M.
| Period end | Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments 3 month | Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments 6 month | Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments 9 month | Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $11.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 |
| 2025-09-30 | -$11.10M 10-Q · filed 2025-11-06 | -$11.10M derived: sum of 2 quarters · filed 2025-11-06 | -$11.10M 10-Q · filed 2025-11-06 | -$27.50M derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | -$16.40M derived: sum of 3 quarters · filed 2026-03-02 | -$17.94M derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-06 | -$16.40M derived: sum of 2 quarters · filed 2026-03-02 | -$17.94M derived: sum of 3 quarters · filed 2026-03-02 | -$17.94M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-12-31 | -$16.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$17.94M derived: sum of 2 quarters · filed 2026-03-02 | -$17.94M derived: sum of 3 quarters · filed 2026-03-02 | -$7.84M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$1.53M 10-Q · filed 2025-11-06 | -$1.53M derived: sum of 2 quarters · filed 2025-11-06 | $8.56M 10-Q · filed 2025-11-06 | -$14.04M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 | $10.10M 10-Q · filed 2025-08-06 | -$12.50M derived: sum of 3 quarters · filed 2026-03-02 | -$10.50M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$10.10M 10-Q · filed 2025-05-06 | -$12.50M derived: sum of 2 quarters · filed 2026-03-02 | -$10.50M derived: sum of 3 quarters · filed 2026-03-02 | |
| 2023-12-31 | -$2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$400.00K derived: sum of 2 quarters · filed 2026-03-02 | -$1.20M 10-K · filed 2026-03-02 | |
| 2023-09-30 | $2.00M 10-Q · filed 2024-11-06 | $1.20M 10-Q · filed 2024-11-06 | ||
| 2022-12-31 | $6.70M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |